Milestones in Parkinson's disease therapeutics

Movement Disorders

Volumn 26, Issue 6, 2011, Pages 1072-1082

  Rascol, Olivier ^a   Lozano, Andres ^b   Stern, Matthew ^c   Poewe, Werner ^d  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Catecholmethyltransferase inhibitors; Deep brain stimulation; Dopamine agonists; Levodopa; Monoamine oxidase B inhibitors; Parkinson's disease; Treatment

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMANTADINE; APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CLOZAPINE; ENTACAPONE; ISTRADEFYLLINE; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; RASAGILINE; RIVASTIGMINE; ROPINIROLE; ROTIGOTINE; SARIZOTAN; SELEGILINE;

BRAIN DEPTH STIMULATION; DEMENTIA; DEPRESSION; DOPAMINERGIC ACTIVITY; DYSKINESIA; DYSTONIA; FOLLOW UP; HALLUCINATION; HUMAN; MOTOR CONTROL; MOTOR DYSFUNCTION; NEUROPATHOLOGY; NEUROPROTECTION; PALLIDOTOMY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SLEEP WAKING CYCLE; SUSTAINED RELEASE FORMULATION;

AMANTADINE; ANTIPARKINSON AGENTS; DEEP BRAIN STIMULATION; DOPAMINE AGENTS; ENZYME INHIBITORS; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PALLIDOTOMY; PARKINSON DISEASE;

EID: 79957603259     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23714     Document Type: Review

References (130)

1. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002; 17(Suppl 4): S1-S166.
2. Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002; 359: 1589-1598.
3. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004; 19: 1020-1028.
4. Fahn S, Elton RL. Unified Parkinson's Disease Rating Scale. In: Marsden CD; Goldstein M CD, eds. Recent Developments in Parkinson's Disease. New York: MacMillan; 1987: 153-163.
5. Hauser RA, Deckers F, Lehert P. Parkinson's disease home diary: further validation and implications for clinical trials. Mov Disord 2004; 19: 1409-1413.
6. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005; 20: 190-199.
7. Shoulson I, Glaubiger GA, Chase TN. On-off response: Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology 1975; 25: 1144-148.
8. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976: 292-296.
9. Lees AJ, Shaw KM, Stern GM. "Off period" dystonia and "on period" choreoathetosis in levodopa-treated patients with Parkinson's disease [Letter]. Lancet 1977; 2: 1034-1034.
10. Jenner P. Preventing and controlling dyskinesia in Parkinson's disease-a view of current knowledge and future opportunities. Mov Disord 2008; 23(Suppl 3): S585-S598.
11. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP): seven cases. Neurology 1985; 35: 949-956.
12. Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1, 2, 3, 6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov Disord 1995; 10: 731-740.
13. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-2508.
14. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006; 5: 677-687.
15. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. Brain 1984; 107: 487-506.
16. Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984; 34: 1131-1136.
17. Kurlan R, Rubin AJ, Miller C, Rivera Calimlim L, Clarke A, Shoulson I. Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations. Ann Neurol 1986; 20: 262-265.
18. Syed N, Murphy J, Zimmerman TJr, Mark MH, Sage JI. Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov Disord 1998; 13: 336-338.
19. Nyholm D, Lewander T, Johansson A, Lewitt PA, Lundqvist C, Aquilonius SM. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008; 31: 63-73.
20. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005; 64: 216-223.
21. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007; 22: 1145-1149.
22. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997; 37: 23-27.
23. Lees AJ. Evidence-based efficacy comparison of tolcapone and entacapone as adjunctive therapy in Parkinson's disease. CNS Neurosci Ther 2008; 14: 83-93.
24. Smith LA, Jackson MJ, Al-Barghouthy G, et al. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Mov Disord 2005; 20: 306-314.
25. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010; 68: 18-27.
26. Kuoppamaki M, Korpela K, Marttila R, et al. Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 2009; 65: 443-455.
27. Stibe CM, Lees AJ, Kempster PA, Stern GM. Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1988; 1: 403-406.
28. Stocchi F, Ruggieri S, Vacca L, Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002; 125: 2058-2066.
29. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002; 17: 1235-1241.
30. Pearce RK, Banerji T, Jenner P, Marsden CD. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 1998; 13: 234-241.
31. Lees AJ, Haddad S, Shaw KM, Kohout LJ, Stern GM. Bromocriptine in parkinsonism. A long-term study. Arch Neurol 1978; 35: 503-505.
32. Rascol A, Guiraud B, Montastruc JL, David J, Clanet M. Long-term treatment of Parkinson's disease with bromocriptine. J Neurol Neurosurg Psychiatry 1979; 42: 143-150.
33. Montastruc JL, Rascol O, Rascol A. A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry 1989; 52: 773-775.
34. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987; 37: 826-828.
35. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484-1491.
36. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 2000; 284: 1931-1938.
37. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: the PELMOPET study. Mov Disord 2006; 21: 343-353.
38. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998; 55(Suppl 1): 23-30.
39. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363: 1179-1183.
40. Rascol O, Pathak A, Bagheri H, Montastruc JL. Dopaminagonists and fibrotic valvular heart disease: further considerations. Mov Disord 2004; 19: 1524-1525.
41. Horvath J, Fross RD, Kleiner-Fisman G, et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord 2004; 19: 656-662.
42. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007; 68: 1108-1115.
43. Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 2008; 24: 2883-2895.
44. Hauser RA, Schapira AH, Rascol O, et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease. Mov Disord 2010; 25: 2542-2549
45. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH. Rotigotine transdermal patch in early Parkinson's disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007; 22: 2398-2404.
46. Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007; 6: 513-520.
47. Frucht S, Fahn S, Shannon KM, Waters CH. A 32-year-old man with progressive spasticity and parkinsonism. Mov Disord 1999; 14: 350-357.
48. Hogl B, Seppi K, Brandauer E, et al. Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. Mov Disord 2003; 18: 319-323.
49. Ferreira JJ, Desboeuf K, Galitzky M, et al. Sleep disruption, daytime somnolence and 'sleep attacks' in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers. Eur J Neurol 2006; 13: 209-214.
50. Brodsky MA, Godbold J, Roth T, Olanow CW. Sleepiness in Parkinson's disease: a controlled study. Mov Disord 2003; 18: 668-672.
51. Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 2009; 8: 929-937.
52. Molina JA, Sainz-Artiga MJ, Fraile A, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 2000; 15: 869-872.
53. Evans AH, Strafella AP, Weintraub D, Stacy M. Impulsive and compulsive behaviors in Parkinson's disease. Mov Disord 2009; 24: 1561 Weintraub D, Koester J, Potenza MN 1570.
54. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589 Weintraub D, Koester J, Potenza MN 595.
55. Rascol O, Brooks DJ, Korczyn AD, et al. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 2006; 21: 1844-1850.
56. Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord 2007; 22: 1317-1319.
57. Watts RL, Lyons KE, Pahwa R, et al. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Disord 2010; 25: 858-866.
58. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009; 66: 563-570.
59. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004; 19: 997-1005.
60. Kurlan R. "Levodopa phobia": a new iatrogenic cause of disability in Parkinson disease. Neurology 2005; 64: 923-924.
61. Langston JW, Irwin I. MPTP: current concepts and controversies. Clin Neuropharmacol 1986; 9: 485-507.
62. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. N Engl J Med 1993; 328: 176-183.
63. Olanow CW, Calne D. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? Neurology 1992; 42(Suppl 4): 13-26; discussion 41-18.
64. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. Ann Neurol 1996; 39: 37-45.
65. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002; 59: 1937-1943.
66. Stern MB, Marek KL, Friedman J, et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord 2004; 19: 916-923.
67. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005; 62: 241-248.
68. Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005; 365: 947-954.
69. Olanow W. Can we achieve neuroprotection with currently available anti-parkinsonian interventions? Neurology 2009; 72(7 Suppl): S59-S64.
70. Finberg JP, Lamensdorf I, Commissiong JW, Youdim MB. Pharmacology and neuroprotective properties of rasagiline. Journal of neural transmission 1996; 48: 95-101.
71. Weinreb O, Amit T, Bar-Am O, Chillag-Talmor O, Youdim MB. Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann N Y Acad Sci 2005; 1053: 348-355.
72. Olanow CW, Hauser RA, Jankovic J, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 2008; 23: 2194-2201.
73. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268-1278.
74. Schapira AH, Olanow CW. Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann Neurol 2008; 64(Suppl 2): S47-S55.
75. Olanow CW, Rascol O. The delayed-start study in Parkinson disease: can't satisfy everyone. Neurology; 74: 1149-1150.
76. Olanow CW, Kieburtz K, Schapira AH. Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol 2008; 64(Suppl 2): S101-S110.
77. Hart RG, Pearce LA, Ravina BM, Yaltho TC, Marler JR. Neuroprotection trials in Parkinson's disease: systematic review. Mov Disord 2009; 24: 647-654.
78. Rascol O. "Disease-modification" trials in Parkinson disease: target populations, endpoints and study design. Neurology 2009; 72(7 Suppl): S51-S58.
79. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. Neuron 2010; 66: 646-661.
80. Agid Y, Cervera P, Hirsch E, et al. Biochemistry of Parkinson's disease 28 years later: a critical review. Mov Disord 1989; 4(Suppl 1): S126-S144.
81. Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov Disord 2005; 20: 919-931.
82. Fox SH, Chuang R, Brotchie JM. Parkinson's disease-opportunities for novel therapeutics to reduce the problems of levodopa therapy. Progr Brain Res 2008; 172: 479-494.
83. Fox MA, Jensen CL, French HT, et al. Neurochemical, behavioral, and physiological effects of pharmacologically enhanced serotonin levels in serotonin transporter (SERT)-deficient mice. Psychopharmacology (Berl) 2008; 201: 203-218.
84. Fox SH, Brotchie JM, Lang AE. Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol 2008; 7: 927-938.
85. Godwin-Austen RB, Frears CC, Bergmann S, Parkes JD, Knill-Jones RP. Combined treatment of parkinsonism with L-dopa and amantadine. Lancet 1970; 2: 383-385.
86. Blanchet PJ, Konitsiotis S, Chase TN. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 1998; 13: 798-802.
87. Chase TN, Oh JD, Konitsiotis S. Antiparkinsonian and antidyskinetic activity of drugs targeting central glutamatergic mechanisms. J Neurol 2000; 247(Suppl 2): II36-42.
88. Stoof JC, Booij J, Drukarch B. Amantadine as N-methyl-D-aspartic acid receptor antagonist: new possibilities for therapeutic applications? Clin Neurol Neurosurg 1992; 94(Suppl): S4-S6.
89. Verhagen Metman L, Del Dotto P, van den Munckhof P, Fang J, Mouradian MM, Chase TN. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease [see comments]. Neurology 1998; 50: 1323-1326.
90. Del Dotto P, Pavese N, Gambaccini G, et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 2001; 16: 515-520.
91. Hauser RA, Shulman LM, Trugman JM, et al. Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 2008; 23: 2177-2185.
92. Eggert K, Squillacote D, Barone P, et al. Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. Mov Disord 2010; 25: 896-905.
93. Goetz CG, Damier P, Hicking C, et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial. Mov Disord 2007; 22: 179-186.
94. Braak H, Del Tredici K. Invited Article: Nervous system pathology in sporadic Parkinson disease. Neurology 2008; 70: 1916-1925.
95. Barone P, Antonini A, Colosimo C, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009; 24: 1641-1649.
96. Poewe W SK. Managing the non-motor symptoms of Parkinson's disease. In: Hallett MP, W, ed. Therapeutics of Parkinson's Disease and Other Movement Disorders. Chichester, UK: Wiley-Blackwell; 2008: 91-120.
97. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518.
98. Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76: 934-939.
99. Aarsland D, Ballard C, Walker Z, et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8: 613-618.
100. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 969-977.
101. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 573-580.
102. Devos D, Dujardin K, Poirot I, et al. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008; 23: 850-857.
103. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology, 2009; 72: 886-892.
104. Zesiewicz TA, Sullivan KL, Arnulf I, et al. Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010; 74: 924-931.
105. Scott RM, Brody JA, Cooper IS. The effect of thalamotomy on the progress of unilateral Parkinson's disease. J Neurosurg 1970; 32: 286-288.
106. Burns RS, Chiueh CC, Markey SP, Ebert MH, Jacobowitz DM, Kopin IJ. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine. Proc Natl Acad Sci U S A 1983; 80: 4546-4550.
107. Lozano AM. Pallidotomy: where are we? Parkinsonism Relat Disord 1996; 2: 53-54.
108. Hutchison WD, Lozano AM, Davis KD, Saint-Cyr JA, Lang AE, Dostrovsky JO. Differential neuronal activity in segments of globus pallidus in Parkinson's disease patients. Neuroreport 1994; 5: 1533-1537.
109. Hutchison WD, Allan RJ, Opitz H, et al. Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease. Ann Neurol 1998; 44: 622-628.
110. Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990; 249: 1436-1438.
111. Aziz TZ, Peggs D, Sambrook MA, Crossman AR. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov Disord 1991; 6: 288-292.
112. Benazzouz A, Gross C, Feger J, Boraud T, Bioulac B. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci 1993; 5: 382-389.
113. Laitinen LV, Bergenheim AT, Hariz MI. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease [see comments]. J Neurosurg 1992; 76: 53-61.
114. Limousin P, Pollak P, Benazzouz A, et al. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995; 345: 91-95.
115. Limousin P, Krack P, Pollak P, et al. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 1998; 339: 1105-1111.
116. Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006; 355: 896-908.
117. Follett KA, Weaver FM, Stern M, et al. Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med 2010; 362: 2077-2091.
118. Freed WJ. Functional brain tissue transplantation: reversal of lesion-induced rotation by intraventricular substantia nigra and adrenal medulla grafts, with a note on intracranial retinal grafts. Biol Psychiatry 1983; 18: 1205-1267.
119. Olanow CW, Fahn S, Langston JW, Godbold J. Selegiline and mortality in Parkinson's disease [see comments]. Ann Neurol 1996; 40: 841-845.
120. Li JY, Englund E, Holton JL, et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008; 14: 501-503.
121. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008; 14: 504-506.
122. Berry AF, Foltynie T. Gene therapy: a viable therapeutic strategy for Parkinson's disease? J Neurol 2011; 258: 179-188.
123. Struppler A, Von UT. [Studies of mechanism of action of apormorphine on Parkinson's tremor.]. Z Klin Med 1953; 152: 46-57.
124. Schwab RS, Mador LV, Lettvin JY. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc 1951; 56: 251-253.
125. Birkmayer W, Hornykiewicz O. Der L-3, 4-Dioxyphenylalanin (=DOPA)-Effekt bei der Parkinson-Akinese. Wiener klinische Wochenschrift 1961.
126. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276: 374-379.
127. Pollak P, Benabid AL, Gervason CL, et al. Long-term effects of chronic stimulation of the ventral intermediate thalamic nucleus in different types of tremor. In: Advances in Neurology. New York: Raven Press; 1993: 408-413.
128. Benabid AL, Pollak P, Gao D, et al. Chronic electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg 1996; 84: 203-214.
129. Benabid AL, Pollak P, Gervason C, et al. Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus. Lancet 1991; 337: 403-406.
130. Hauser RA, Freeman TB, Snow BJ, et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Arch Neurol 1999; 56: 179-187.